Zobrazeno 1 - 10
of 810
pro vyhledávání: '"β-lactamase inhibitor"'
Autor:
Lamiaa A. Al-Madboly, Mohamed A. Abd El-Salam, Jairo K. Bastos, Shaimaa Aboukhatwa, Rasha M. El-Morsi
Publikováno v:
Microbial Cell Factories, Vol 23, Iss 1, Pp 1-16 (2024)
Abstract β-lactam resistance is a significant global public health issue. Outbreaks of bacteria resistant to extended-spectrum β-lactams and carbapenems are serious health concerns that not only complicate medical care but also impact patient outco
Externí odkaz:
https://doaj.org/article/301f0b1e9700487dab5463f1f6f6cd94
Autor:
Zhuoren Ling, Alistair James Macdonald Farley, Aditya Lankapalli, Yanfang Zhang, Shonnette Premchand-Branker, Kate Cook, Andrei Baran, Charlotte Gray-Hammerton, Claudia Orbegozo Rubio, Edgars Suna, Jordan Mathias, Jürgen Brem, Kirsty Sands, Maria Nieto-Rosado, Maria Mykolaivna Trush, Nadira Naznin Rakhi, Willames Martins, Yuqing Zhou, Christopher Joseph Schofield, Timothy Walsh
Publikováno v:
Engineering, Vol 38, Iss , Pp 124-132 (2024)
This work explores the potential of a triple combination of meropenem (MEM), a novel metallo-β-lactamase (MBL) inhibitor (indole-2-carboxylate 58 (InC58)), and a serine-β-lactamase (SBL) inhibitor (avibactam (AVI)) for broad-spectrum activity again
Externí odkaz:
https://doaj.org/article/7e07e91858ca42e3a0aa3e27ecdb3e70
Autor:
Jung Hun Lee, Sang-Gyu Kim, Kyung-Min Jang, Kyoungmin Shin, Hyeonku Jin, Dae-Wi Kim, Byeong Chul Jeong, Sang Hee Lee
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 39, Iss 1 (2024)
AbstractThe urgent demand for effective countermeasures against metallo-β-lactamases (MBLs) necessitates development of novel metallo-β-lactamase inhibitors (MBLIs). This study is dedicated to identifying critical chemical moieties within previousl
Externí odkaz:
https://doaj.org/article/c847db5836704a938c7f1d43908ced9e
Autor:
Maria F. Mojica, Elise T. Zeiser, Scott A. Becka, David A. Six, Greg Moeck, Krisztina M. Papp-Wallace
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 11 (2024)
ABSTRACT Taniborbactam (formerly VNRX-5133) is a novel, investigational boronic acid β-lactamase inhibitor. The combination of cefepime (FEP) with taniborbactam is active against Enterobacterales carrying class A, B, C, and/or D enzymes. We assessed
Externí odkaz:
https://doaj.org/article/a37186db696742128c58a99fe618b13a
Autor:
Izumi Yamatani, Akio Aono, Keiji Fujiwara, Takahiro Asami, Keisuke Kamada, Yuta Morishige, Yuriko Igarashi, Kinuyo Chikamatsu, Yoshiro Murase, Hiroyuki Yamada, Akiko Takaki, Kosaku Komiya, Satoshi Mitarai
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 7 (2024)
ABSTRACT Non-tuberculosis mycobacteria (NTM), particularly Mycobacterium abscessus subsp. abscessus (M. abscessus), are increasingly being recognized as etiological agents of NTM pulmonary disease. However, treatment options for M. abscessus are limi
Externí odkaz:
https://doaj.org/article/376011df65c344ebae16600a875edb67
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Urinary tract infection (UTI) is the most prevalent urological condition worldwide. Choosing appropriate antibiotics for patients who have fever before receiving a culture result is challenging. This retrospective study enrolled patients 394
Externí odkaz:
https://doaj.org/article/0d7aee81532a471bb23da64935a43472
Publikováno v:
Health Science Reports, Vol 7, Iss 8, Pp n/a-n/a (2024)
Abstract Background and Aims The prevalence of carbapenemase‐producing Enterobacterales (CPE) continues to increase worldwide. Combination of β‐lactam and novel β‐lactamase inhibitors introduce a revolutionary treatment option for CPE. Ceftaz
Externí odkaz:
https://doaj.org/article/c08ed9f3188d4357a3552361c61297e7
Autor:
Wesam H. Abdulaal, Nabil A. Alhakamy, Amer H. Asseri, Mohamed F. Radwan, Tarek S. Ibrahim, Solomon Z. Okbazghi, Hisham A. Abbas, Basem Mansour, Aly A. Shoun, Wael A. H. Hegazy, Mahmoud Saad Abdel-Halim
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
The development of resistance to carbapenems in Klebsiella pneumoniae due to the production of metallo-β-lactamases (MBLs) is a critical public health problem because carbapenems are the last-resort drugs used for treating severe infections of exten
Externí odkaz:
https://doaj.org/article/d110b12d49894e479ecad54a0fad2c92
Autor:
Xinhui Li, Jisheng Zhang, Jianmin Wang, Wenzhang Long, Xushan Liang, Yang Yang, Xue Gong, Jie Li, Longjin Liu, Xiaoli Zhang
Publikováno v:
Frontiers in Microbiology, Vol 15 (2024)
Isolates coproducing serine/metallo-carbapenems are a serious emerging public health threat, given their rapid dissemination and the limited number of treatment options. The purposes of this study were to evaluate the in vitro antibacterial activity
Externí odkaz:
https://doaj.org/article/91ee6d72f761414c8338d63fc03131d6
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundGram-negative bacteria is a global public health problem. Treatment options include novel beta-lactamase inhibitors.ObjectivesThe objective of this study was to collect information on the efficacy and safety of novel β-lactamase inhibitor
Externí odkaz:
https://doaj.org/article/d18b5b4ff33a4e7fb007c8c2b831d4fe